GPCRs (G-protein-coupled receptors) are a large family of structurally related proteins which mediate their effects by coupling to G-proteins. The V 1a R (V 1a vasopressin receptor) is a member of a family of related GPCRs that are activated by vasopressin {AVP ([Arg 8 ]vasopressin)}, OT (oxytocin) and related peptides. These receptors are members of a subfamily of Family A GPCRs called the neurohypophysial peptide hormone receptor family. GPCRs exhibit a conserved tertiary structure comprising a bundle of seven TM (transmembrane) helices linked by alternating ECLs (extracellular loops) and ICLs (intracellular loops). The cluster of TM helices is functionally important for ligand binding, and, furthermore, activation of GPCRs involves movement of these TM helices. Consequently, it might be assumed that the extracellular face of GPCRs is composed of peptide linkers that merely connect important TM helices. However, using a systematic mutagenesis approach and focusing on the N-terminus and the second ECL of the V 1a R, we have established that these extracellular domains fulfil a range of important roles with respect to GPCR signalling, including agonist binding, ligand selectivity and receptor activation.
Introduction
GPCRs (G-protein-coupled receptors) are a large family of structurally related proteins which mediate their effects by coupling to G-proteins. Several hundred GPCRs have now been cloned. Despite being activated by a wide variety of stimuli from photons to glycoproteins, these receptors exhibit primary sequence homology and a conserved tertiary structure comprising a bundle of seven TM (transmembrane) domains [1] . Analysis of these sequences has revealed that GPCRs can be further categorized into the rhodopsin/β-adrenergic receptor family (Family A), the secretin receptor family (Family B) and metabotropic glutamate receptors (Family C) [2] [3] [4] . The largest and most extensively characterized of these is the rhodopsin/β-adrenergic receptor family [5] . All of these different classes of GPCR exhibit a common protein fold comprising seven TM domains connected by alternating ECLs (extracellular loops) and ICLs (intracellular loops). The extracellular face of GPCRs comprises the Nterminus plus the ECLs. These are the most variable structural elements of the receptor with respect to both length and sequence. Even subtypes in the same receptor family can exhibit very low sequence homology in these segments. Consequently, it would not be unreasonable, perhaps, to conclude that this lack of sequence conservation may be indicative of a lack of functional significance. Furthermore, the crystal structure of bRho (bovine rhodopsin) confirmed that the chromophore retinal is located deep within the helical bundle [1] . Likewise, the ligand binding site for small ligands such as biogenic amines, and non-peptide analogues of peptide hormones, has been mapped to a pocket defined by the TM cluster of the relevant GPCR. Although ICLs are required for G-protein interaction and receptor regulation via kinases, arrestins, scaffolding proteins, etc., a role for the ECLs is not so apparent perhaps. An exception to this is ECL2 (second ECL), which in the bRho crystal structure forms contacts with 11-cis-retinal by plunging deep into the TM bundle [1] . However, there is now increasing evidence that this supposed lack of function is not the case and that these extracellular elements fulfil important functional roles within the GPCR architecture.
The neurohypophysial peptide hormone receptor family
The neurohypophysial hormones AVP ([Arg 8 ]vasopressin) and OT (oxytocin) are structurally homologous. Both are nonapeptides, possess an intramolecular disulfide bond and have sequences which differ at just two positions. Nevertheless, these neuropeptides have discrete physiological roles. AVP exhibits a plethora of responses in addition to the wellcharacterized vasopressor and antidiuretic actions [6] and OT stimulates uterine contraction at parturition and promotes lactation [7] . The physiological effects of both of these hormones are mediated by receptors which belong to the rhodopsin/β-adrenergic receptor family. Four different receptor subtypes have been defined and cloned. The V 1a R (V 1a vasopressin receptor), the V 1b R (V 1b vasopressin receptor) and the OTR (OT receptor) stimulate phosphoinositidase C, whereas the V 2 R stimulates adenylate cyclase [8, 9] . The V 1a R is widely distributed and mediates nearly all of the actions of AVP with the notable exceptions of antidiuresis [V 2 R (V 2 vasopressin receptor)-mediated] and corticotropin [also known as ACTH (adrenocorticotrophic hormone)] secretion (V 1b R-mediated). All four receptor subtypes exhibit different, but related, pharmacological profiles [10] . In addition to overlapping ligand-binding characteristics, these receptors share certain sequence motifs which identify these receptors as a subfamily of peptide GPCRs [11, 12] referred to as the neurohypophysial peptide hormone family of GPCRs. This subfamily of peptide GPCRs also includes the receptors for vasotocin, mesotocin and isotocin which are evolutionary precursors of AVP and OT [13] .
The role of the N-terminus in agonist binding and receptor activation
The largest single component of the extracellular face of the V 1a R is the N-terminus. This domain is composed of 48 amino acid residues and is N-glycosylated at two positions: Asn 14 and Asn 27 [14, 15] . To address the role of the N-terminal domain of the V 1a R in ligand recognition, a series of receptor constructs was made with progressively greater N-terminal deletions. Initially, three mutant receptors were engineered termed [ 2-23]V 1a R, [ 2-36]V 1a R and [ 2-47]V 1a R respectively, where the numbering refers to the amino acid residues deleted. The pharmacological characteristics of the truncated receptor constructs were investigated and compared with wild-type receptors, following expression in HEK-293T (human embryonic kidney) cells [16] . The wildtype receptor and truncated constructs were all expressed at the same level of approx. 1-2 pmol/mg of protein, indicating that no essential information for the assembly of functional V 1a Rs is provided by the N-terminal sequence. In addition, oligosaccharide modification does not have a role in ligand recognition, or receptor folding, as the [ 2-36]V 1a R construct exhibited wild-type pharmacology, despite lacking both of these glycosylation sites. This conclusion has been corroborated by a separate study in which we replaced both of these asparagine residues using site-directed mutagenesis [14] . However, further truncations of the Nterminus to Asn 47 ([ 2-47]V 1a R) resulted in a profound decrease in agonist affinity with the K d for AVP increasing approx. 2000-fold. In marked contrast, the affinity of the three antagonists for the [ 2-47]V 1a R was not markedly different from the wild-type. This retention of high-affinity antagonist binding by the truncated V 1a R constructs was important practically as it allowed the altered binding characteristics of agonists to be determined quantitatively using the antagonist
2 AVP as tracer. Furthermore, the wildtype binding characteristics of the three different classes of antagonist established that the folding and final conformation of the [ 2-47]V 1a R construct was not grossly perturbed by the deletion. Consequently, a segment of the N-terminus had been identified which was required for high-affinity AVP binding. In addition, this segment was also required for intracellular signalling as assessed by AVP-induced accumulation of InsP-InsP 3 [16] . Detailed investigation of the role of individual residues in this segment of the N-terminus by alanine-scanning mutagenesis revealed that the major contribution to high affinity agonist binding was provided by a single residue, Arg 46 (see Figure 1 ) [17] .
[R46A]V 1a R also had disrupted second messenger generation, with the EC 50 for AVP-induced InsP-InsP 3 production increasing 65-fold compared with wild-type V 1a R. The same experimental approaches were applied to investigate the role of the Nterminus of the OTR, another member of this subfamily of peptide-GPCRs. These studies revealed that mutation of a single arginine residue (Arg 34 ) in the distal N-terminus (corresponding to Arg 46 of the rat V 1a R) disrupted agonist binding and intracellular signalling, but did not perturb antagonist binding (peptide and non-peptide) [18, 19] . These observations with the V 1a R and OTR, together with the very high level of conservation of an arginine residue at this locus throughout the neurohypophysial peptide hormone receptor family, suggested a conservation of function for an arginine residue in the distal N-terminus. The N-terminus of other GPCRs with peptide ligands has been shown to provide agonist binding contacts, including the angiotensin AT 1 receptor [20] and the neurokinin NK 1 receptor [21] . However, this is not a universal situation. In contrast, this domain of the κ-opiate receptor is required for antagonist binding, but not agonist binding [22] .
Analysis of sequence alignments revealed that the sequence motif RX 3 (L/V)X 3 EX 3 L in the N-terminal/TM1 juxtamembrane domain of the V 1a R is conserved throughout the vertebrate neurohypophysial peptide hormone GPCR family, perhaps indicating functional importance. Characterization of the mutant construct [E54A]V 1a R revealed that Glu 54 (located two turns below Arg 46 ) is critical for highaffinity binding of AVP and intracellular signalling, but was not required for the binding of any of the three classes of antagonist [23] . This pharmacological profile is remarkably similar to that exhibited by [R46A]V 1a R described above. Furthermore, a glutamate residue is absolutely conserved at residue 1.35 throughout the neurohypophysial peptide hormone receptor family cloned to date (residues in TMs are referred to by residue number and the nomenclature of Ballesteros and Weinstein [24] ). Given that these two residues are stacked on the same face of an α-helix and located two turns apart, it was possible that Arg 46 and Glu 54 engaged in a mutual charge-charge interaction [23] . If Arg 46 and Glu 54 interact in the wild-type V 1a R (Figure 1) , then a construct possessing a double mutation in which these two residues are reversed would be expected to preserve this mutual interaction and therefore bind agonist with high affinity and signal effectively. Such a rationale was applied to demonstrate an interaction between Asn 87 (2.50) and Asp 318 (7.49) in TM2 and TM7 respectively of the gonadotropin-releasing hormone receptor [25] . However, mutual interaction between Glu 54 and Arg 46 was excluded when a V 1a R construct Individual residues are shown as circles. White letters on black circles indicate specific residues cited in this paper. These residues are also identified by an arrow and the residue number. The tops of TMI-TMVII are shown as cylinders.
with reciprocal mutation ([R46E/E54R]V 1a R) failed to signal and had very low affinity for AVP. This study established that Glu 54 and Arg 46 operate independently, fulfilling two different roles which support high affinity agonist-receptor interaction and effective intracellular signalling [23] .
Functional importance of the interface of ECL2 with the top of TMIII
The ECL2 domain of bRho forms a β-hairpin that plunges down into the TM bundle, forming a lid over the bound retinal which shields it from the extracellular milieu. This protein fold positions residues in the second β-strand (β4) of this ECL2 hairpin structure in close proximity to the chromophore [1] . The position of ECL2 is constrained by a disulfide bond between a cysteine residue in ECL2 and another at the top of TMIII (Cys 3.25 ). This disulfide bond is conserved in nearly all Family A GPCRs and contributes to structural integrity of the receptor. Recently, the role of individual residues in ECL2 of the V 1a R has been investigated by systematic alanine substitution of the entire loop. This revealed that certain aromatic residues were important for normal function [26] , including residues Trp 206(C+1) and Phe 209(C+4) located in ECL2 near to the conserved disulfide bond (residues in ECL2 are referred to by the nomenclature of Conner et al. [26] ). Immediately adjacent to the TMIII Cys 124(3.25) , at the other end of this disulfide bond is Arg 125(3.26) (Figure 1 ). The absolute conservation of this arginine residue throughout the neurohypophysial peptide hormone receptor family implies functional importance. Mutagenesis experiments established that a positive charge was required at this position and that introduction of a negative charge at this locus ([R125D]V 1a R) ablated specific binding of the radio tracers (agonist and antagonist) and impaired signalling. The requirement for a positive charge at this locus is supported by a report that the naturally occurring mutation R113W in the human V 2 R (which corresponds to Arg 125 in the V 1a R) causes the receptor dysfunction responsible for NDI (nephrogenic diabetes insipidus) in some patients [27] . Molecular modelling revealed that Arg 125(3.26) is located near to the extracellular end of TMIII, where it interacts with lipids to help restrain the orientation of TMIII. This arginine-lipid interaction has been referred to as 'snorkelling' [28] . Mutating to a negatively charged residue at this locus in [R125D]V 1a R resulted in disruption of the lipid packing around the top of TMIII, allowing greater solvent access into the helical bundle. Interestingly, a positive charge is conserved at this position in GPCRs with peptide ligands, but a negative charge is conserved in GPCRs with amine ligands. This difference between peptide GPCRs and amine GPCRs may reflect the different location of these ligands' binding sites within the receptor architecture, with amines binding deep in the TM helical bundle and peptides binding to the TM domain and ECLs.
Concluding remarks
The extracellular domains of GPCRs sometimes appear remote with respect to the overall receptor architecture and may be thought initially to be on the periphery of the fundamental molecular events associated with agonistinduced activation and G-protein coupling. However, it is becoming increasingly clear that this is not the case and that these extracellular segments have a crucial role in many aspects of GPCR function including ligand binding and receptor activation. 
